Upload
others
View
1
Download
0
Embed Size (px)
Citation preview
Preoperative antithrombotic
management: before cardiac surgery
S. Demertzis
Facts
> CABG-related bleeding complications & perioperative acute coronary
events are strongly influenced by the management of pre- & postop
antithrombotic therapy
> Significant postop bleeding with transfusions of blood & blood products
increase the risk of death & compromise the long-term benefit of CABG
> Lack of randomized trials on different strategies
It’s all a matter of perspective…
Activated platelets
Hemostasis in surgery (the good)
Suture in arterial lumen
(x1000 magnification - REM)
Stent thrombosis - acute MI (the bad)
… and mastery of navigation and troubleshooting!
The Odyssey
Odysseus is hindered by the efforts of Poseidon and the
sea monsters throughout the ocean. Odysseus faced
both Charybdis and Scylla while rowing through a narrow
channel. He ordered his men to avoid Charybdis thus
forcing them to pass near Scylla, which resulted in the
death of six of his men.
Later, stranded on a raft, Odysseus was swept back
through the strait to face Scylla and Charybdis once
more. This time, Odysseus passed near Charybdis. His
raft was sucked into Charybdis' maw, but he survived by
clinging to a fig tree growing on a rock over her lair. On
the next outflow of water, his raft was expelled.
Odysseus recovered it and paddled away safely.
Cardiac Surgery under Double Antiplatelet Therapy (DAPT)
Hongo et al. JACC 2002; 40(2): 231-7.
Reoperation for bleeding after CABG
0,00%
1,75%
3,50%
5,25%
7,00%
8,75%
no cplopidogrel n=165 clopidogrel n=59
10 x
0
6
12
18
24
30
clopidogrel n=189 prasugrel n=179
CABG-related TIMI major bleeding
TRITON–TIMI 38 study, N Engl J Med 2007;357:2001-15.
4 x
An important issue
Current recommendations
Prospective observational study n= 405 consecutive CABG patients with ACS
aspirin and ticagrelor (n = 173) or aspirin and clopidogrel (n = 232).
EJCTS 46 (2014) 699-705
Coronary artery bypass grafting-related bleeding
complications in real-life acute coronary syndrome
patients treated with clopidogrel or ticagrelor
Know your enemy and know yourself and you
can fight a hundred battles without disaster.
(Sun Tzu - The Art of War (chinese: trad.孫子兵法, simp. 孙子兵法, lit. "Master Sun's Rules for Army")
Casso G. et al.(2015). Point-of-care platelet function tests. In C. E. Marcucci & P Schoettker (Ed.),
Perioperative Hemostasis (pp. 45-63). Berlin Heidelberg, Springer.
Primary hemostasis - Platelet physiology
Antiplatelet agents
mod. from Chassot et al. in Marcucci, Schoettker (eds.)
Perioperative Hemostasis, Springer 2015
Substance Commercial product Route Half-life
Clopidogrel Plavix p.o. 7.5 h
Prasugrel Effient, Iscover p.o. 3.7 h
Ticagrelor Brilique, Brilinta, Possia p.o. 7-10 h
Cangrelor Kengrexal i.v. 3 min
Abciximab ReoPro i.v. 23 h
Eptifibatid Integrillin i.v. 2.5 h
Tirofiban Aggrastat i.v. 2 h
A game changer:
Point-of-Care platelet & coagulation testing
ROTEM® Multiplate®
Multiplate® - concept
Casso G. et al.(2015). Point-of-care platelet function tests. In C. E. Marcucci & P Schoettker (Ed.),
Perioperative Hemostasis (pp. 45-63). Berlin Heidelberg, Springer.
Multiplate® - concept II
Multiplate® - working mechanism
Multiplate® - working mechanism
Multiplate® - Summary
Assessment of drug effect
+ −
• Aspirin
• P2Y12 inhibitors
• GP IIb/IIIa inhibitors
• Rapid (<10 min) and easy test
• Whole blood, no requirements for
sample preparation
• Low sample volume (0.3ml/test)
• Multiple agonists available allowing
a wide range of different acquired
and inherited platelet dysfunction
detection
• Requires pipetting
(consider Verify Now®)
• Dependent to levels of
calcium (Hirudin is
preferred to citrate)
• Sensitive to
thrombocytopenia
(PC > 150 G/l ASPI test,
>100 G/l ADP and COL
test, > 50 G/l TRAP test)
Casso G. et al.(2015). Point-of-care platelet function tests. In C. E. Marcucci & P Schoettker (Ed.),
Perioperative Hemostasis (pp. 45-63). Berlin Heidelberg, Springer.
Ann Thorac Surg 2011;91:123–30
ADP Test AUC < 31 U
Retrospective study n=87
Preoperative evaluation of M-ADP
ROTEM® - the new thrombelastogram
EXTEM
Tissue thromboplastin -tissue factor
INTEM
Contact phase - intrinsic system
FIBTEM
As in EXTEM but with blocked platelets
- fibrin formation & polymersation
APTEM
Aprotinin inhibits fibrinolysis in vitro
HEPTEM
As in INTEM but with blocked heparin
Clinical scenarios
Acute STEMI - PCI not successful / too risky: emergent surgery
> high probability of active DAPT (prehospital protocols) and periprocedural GP IIb/IIa antagonists
> platelet function test + alert the blood bank!
> hemorrhagic complications highly probable
Acute / subacute NSTEMI - subacute STEMI: stable hospitalized patient for urgent surgery
> withdrawal of DAPT
> bridge-to-surgery with i.v. heparine, GP IIb/IIa antagonists (soon with cangrelor)
> timing of surgery according to platelet- and coagulation testing (POC)
Acute NSTEMI - instable patient: urgent / emergent surgery
> pre-hospital protocols should be conservative regarding DAPT
> bridge-to-surgery with i.v. heparine, GP IIb/IIa antagonists (soon with cangrelor) possible
Conclusions
> Major “diffuse” bleeding after CABG is a serious complication with a
significant impact on the final outcome - it has to be considered
seriously
> DAPT introduction in the pre-hospital setting has to be conscious
and wise!
> Discontinuation of DAPT ± possible bridging (heparine, GP IIb/IIa
antagonists, cangrelor) is advised - clinical judgement!
> Platelet function monitoring (POC) can guide the Extended Heart
Team in the timing / scheduling of surgery
Thanks to the Extended Heart Team!
Special thanks to Dr. Casso and Dr. Cassina (Cardio-anaesthesiology & ICU) for the precious
help in this difficult navigation (POC) and for their support for this presentation.
Invasive
CardiologyNon invasive
Cardiology
Cardiac Surgery
Cardio-anaesthesiology & Intensive Care Unit